New Sleep Apnea Pill Could Replace Hated CPAP Machines by 2027
A new pill for sleep apnea could soon offer an alternative to the widely disliked CPAP machine. Apnimed, the company behind the treatment, has submitted its application to the FDA and aims for a 2027 launch. The condition affects up to 80 million Americans and raises serious health risks if left untreated.
Apnimed’s pill, named Rezon, works by stimulating the brain stem to prevent throat muscles from fully relaxing during sleep. This approach avoids the need for a CPAP machine, which many patients find uncomfortable. The drug combines two existing medications into a single arrow-shaped tablet.
The company filed its New Drug Application (NDA) with the FDA on 24 January 2025. If approved, the pill could become a major commercial success, with potential sales reaching billions. Apnimed has already raised $260 million from investors, valuing the firm at around $400 million. Untreated sleep apnea has been linked to higher risks of heart disease, strokes, and neurodegenerative conditions like Parkinson’s and Alzheimer’s. The company is now preparing for an IPO to fund its commercial launch, targeting the first half of 2027 for market release.
The pill’s success could transform treatment for millions who struggle with CPAP devices. Apnimed’s next steps include securing FDA approval and scaling production. If all goes to plan, the drug may reach patients within the next two years.
